A carregar...
Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
The brain is the most common site of first metastasis for patients with HER2-positive breast cancer treated with HER2-targeting drugs. However, the development of effective therapies for breast cancer brain metastases (BCBMs) is limited by an incomplete understanding of the mechanisms governing drug...
Na minha lista:
| Publicado no: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5899637/ https://ncbi.nlm.nih.gov/pubmed/29437794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3351 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|